Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

REGN

Regeneron Pharmaceuticals, Inc.

Dec 08 • 04:00PM ET

840.14

Dollar change -9.04
Percentage change -1.06	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	NDX, S&P 500	P/E	23.96	EPS (ttm)	35.06	Insider Own	4.30%	Shs Outstand	107.80M	Perf Week	3.10%
Market Cap	91.53B	Forward P/E	19.19	EPS next Y	43.78	Insider Trans	-1.04%	Shs Float	104.26M	Perf Month	2.11%
Income	3.99B	PEG	10.89	EPS next Q	10.89	Inst Own	85.20%	Short Float / Ratio	1.34% / 3.08	Perf Quarter	0.79%
Sales	13.10B	P/S	6.99	EPS this Y	-4.89%	Inst Trans	-0.34%	Short Interest	1.40M	Perf Half Y	12.54%
Book/sh	228.90	P/B	3.67	EPS next Y	2.33%	ROA	13.34%	Target Price	921.33	Perf Year	9.93%
Cash/sh	90.99	P/C	9.23	EPS next 5Y	2.20%	ROE	17.22%	52W Range	668.00 - 853.97	Perf YTD	16.45%
Dividend	-	P/FCF	19.88	EPS past 5Y	29.89%	ROI	14.46%	52W High	-1.62%	Beta	0.15
Dividend %	-	Quick Ratio	4.47	Sales past 5Y	21.29%	Gross Margin	82.84%	52W Low	25.77%	ATR	15.86
Employees	11851	Current Ratio	5.18	Sales Q/Q	14.53%	Oper. Margin	33.69%	RSI (14)	63.09	Volatility	2.28% 1.90%
Optionable	Yes	Debt/Eq	0.11	EPS Q/Q	-23.81%	Profit Margin	30.47%	Rel Volume	0.82	Prev Close	849.18
Shortable	Yes	LT Debt/Eq	0.11	Earnings	Nov 02 BMO	Payout	0.00%	Avg Volume	454.81K	Price	840.14
Recom	1.82	SMA20	4.01%	SMA50	3.31%	SMA200	6.87%	Volume	374,330	Change	-1.06%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976
Mar-24-23	Upgrade	Jefferies	Hold → Buy	$675 → $925
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform	$775 → $875
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight	$850
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line	$760
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$625 → $851
Sep-09-22	Upgrade	Jefferies	Underperform → Hold	$536 → $675
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$630
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$625
Jun-06-22	Initiated	Jefferies	Underperform	$536
May-23-22	Initiated	SVB Leerink	Outperform	$738
Jan-05-22	Downgrade	BofA Securities	Neutral → Underperform	$675 → $575
Jan-03-22	Upgrade	Bernstein	Mkt Perform → Outperform	$660

Show Previous Ratings

Today 12:07PM	Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate (Zacks)
07:45AM	Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire? (Motley Fool)
Dec-07-23 07:44PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
05:34PM	Why Regeneron could be the top biotech investment in 2024 (Yahoo Finance Video)
07:00AM	Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma (GlobeNewswire)
02:30AM	Loading…
02:30AM	Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO (GlobeNewswire)
Dec-06-23 03:45PM	Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise (Investor's Business Daily)
Dec-04-23 06:19AM	EyePoint sees stock surge on AMD drug trial data (BioPharma Dive)
Dec-02-23 02:05PM	JP Morgans Top 15 Stock Picks for 2023 and Now (Insider Monkey)
Nov-30-23 04:05PM	Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio (GlobeNewswire)
Nov-27-23 04:27PM	Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales (Investor's Business Daily)
10:35AM	Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study (Zacks)
06:00AM	Regeneron, Sanofi to seek new Dupixent approval in US after COPD success (BioPharma Dive)
01:30AM	Dupixent (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease (GlobeNewswire)
Nov-24-23 11:29AM	Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead? (Zacks)
04:05PM	Loading…
Nov-15-23 04:05PM	Regeneron Announces Investor Conference Presentation (GlobeNewswire)
Nov-13-23 09:00AM	Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF) (GlobeNewswire)
Nov-09-23 10:01PM	7 Underappreciated Biotech Stocks to Pick Up on the Cheap (InvestorPlace)
09:53AM	2 Soaring Stocks to Buy and Hold (Motley Fool)
Nov-07-23 11:15PM	Regeneron Pharmaceuticals (REGN): Bronte Capital's Biggest Winner of This Quarter (Insider Monkey)
Nov-06-23 04:01PM	Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi (Investor's Business Daily)
Nov-03-23 11:47AM	Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues (Zacks)
11:40AM	HRMY vs. REGN: Which Stock Should Value Investors Buy Now? (Zacks)
11:37AM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
10:59AM	Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:22AM	Morning Brew: Jobs Growth Moderates, Fortinet Plunges, Apple Dips, and Regeneron Upgraded (GuruFocus.com)
09:13AM	Regeneron Is Pointed Higher, But Here's the Price Where I'd Be a Buyer (TheStreet.com)
08:42AM	Q3 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH (GlobeNewswire)
Nov-02-23 04:06PM	Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers (Investor's Business Daily)
12:31PM	Loading…
12:31PM	Regeneron (REGN) Q3 Earnings & Sales Top, Eylea Sales Decline (Zacks)
09:38AM	Regeneron Edges Higher On Third-Quarter Beat As High-Dose Eylea Delivers (Investor's Business Daily)
09:30AM	Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:38AM	Regeneron Pharmaceuticals Inc (REGN) Reports 15% Revenue Growth in Q3 2023 (GuruFocus.com)
06:44AM	UPDATE 4-Regeneron sees strong initial demand for higher-dose Eylea (Reuters)
06:42AM	Regeneron sees strong initial demand for higher-dose Eylea (Reuters)
06:40AM	Regeneron: Q3 Earnings Snapshot (Associated Press Finance)
06:34AM	Regeneron beats quarterly profit estimates on eczema treatment strength (Reuters)
06:30AM	Regeneron Reports Third Quarter 2023 Financial and Operating Results (GlobeNewswire)
Nov-01-23 04:00PM	EYLEA HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema (GlobeNewswire)
11:28AM	Curious about Regeneron (REGN) Q3 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Oct-31-23 10:01AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-27-23 08:37AM	Regeneron (REGN) to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-26-23 04:00PM	Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss (GlobeNewswire)
10:02AM	Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-25-23 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
09:53AM	Stock-Split Watch: Could These 2 Growth Stocks Be Next? (Motley Fool)
08:30AM	Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030 (PR Newswire)
Oct-23-23 09:40AM	Intellia (NTLA) Focuses on Developing Gene-Editing Therapies (Zacks)
Oct-22-23 02:59PM	Dupixent (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE) (GlobeNewswire)
Oct-21-23 08:48AM	Libtayo (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC) (GlobeNewswire)
Oct-20-23 05:00PM	Regeneron and Sanofi Provide Update on Dupixent (dupilumab) sBLA for Chronic Spontaneous Urticaria (GlobeNewswire)
Oct-18-23 09:30AM	Regeneron builds on Together for CHANGE initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN (GlobeNewswire)
09:00AM	Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry (GlobeNewswire)
Oct-16-23 09:26AM	2 Healthcare Stocks Near 52-Week Highs Still Worth Buying (Motley Fool)
Oct-15-23 06:05PM	Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO (GlobeNewswire)
Oct-14-23 10:44AM	AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points (Investor's Business Daily)
Oct-13-23 02:35PM	Regeneron Bulls, Bears Clash: Will Biotech Get Eylea Mojo Back? (Investor's Business Daily)
Oct-10-23 02:00PM	Down 45%, Is Intellia a Buy? (Motley Fool)
Oct-09-23 02:03AM	14 Best Cancer Stocks To Buy Now (Insider Monkey)
Oct-07-23 03:33PM	12 Stock Picks From Our Healthcare Roundtable Pros. Weight Loss Isnt the Only Big Deal in Medicine. (Barrons.com)
Oct-06-23 12:10PM	Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
04:59AM	The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna (Zacks)
Oct-05-23 12:32PM	Decoding Regeneron Pharmaceuticals (REGN)'s Valuation: Is It Truly Worth the Price? (GuruFocus.com)
10:58AM	Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More (Zacks)
09:43AM	EYLEA HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA (GlobeNewswire)
09:15AM	This Market-Beating Stock Just Gave Investors More Reasons to Invest (Motley Fool)
05:50AM	Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close) (Motley Fool)
Oct-04-23 09:27AM	Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies (Zacks)
Oct-03-23 07:58AM	UPDATE 1-Regeneron, Intellia to make gene editing therapies in expanded collaboration (Reuters)
07:08AM	Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapies (Reuters)
07:00AM	Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases (GlobeNewswire)
Sep-30-23 05:30AM	Stock Split Watch: Is Regeneron Pharmaceuticals Next? (Motley Fool)
Sep-29-23 08:30AM	Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review (GlobeNewswire)
Sep-28-23 04:05PM	Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023 (GlobeNewswire)
Sep-27-23 02:47PM	Regeneron Pharmaceuticals Stock Earns 85 RS Rating (Investor's Business Daily)
Sep-26-23 08:11AM	FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE (Zacks)
01:29AM	Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review (GlobeNewswire)
Sep-25-23 05:13PM	Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
09:07AM	The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management (Zacks)
08:34AM	Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss (GlobeNewswire)
06:30AM	Regeneron finalizes acquisition of Decibel Therapeutics, enhancing gene therapy portfolio (Investing.com)
Sep-22-23 02:57PM	Top Stock Reports for Amazon.com, Boeing, Regeneron & Others (Zacks)
Sep-20-23 10:07AM	This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost (Motley Fool)
08:28AM	Regenerons Eylea HD Gets FDA Approval, Boosting Companys Growth Outlook (Investing.com)
Sep-15-23 09:32AM	Shake Shack upgraded, DoorDash downgraded: Wall Street's top analyst calls (The Fly)
Sep-09-23 06:55AM	3 Unstoppable Growth Stocks to Buy Right Now (Motley Fool)
Sep-08-23 05:39PM	Regeneron says CFO Landry to retire in February (Reuters)
04:58PM	U.S. health agency, Regeneron extend partnership to develop monoclonal antibodies (Reuters)
04:46PM	Regeneron Provides Update on Planned Chief Financial Officer Transition (GlobeNewswire)
04:45PM	Regeneron Announces Updates to Board of Directors (GlobeNewswire)
09:53AM	2 Top Biotech Stocks to Buy in September (Motley Fool)
Sep-07-23 11:30AM	Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-06-23 11:14AM	12 Best Healthcare ETFs To Buy (Insider Monkey)
Aug-31-23 01:43PM	Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD (Zacks)
Aug-25-23 10:15AM	Is Regeneron Stock a Buy Now? (Motley Fool)
09:16AM	The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics (Zacks)
Aug-24-23 10:15AM	Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More (Zacks)
Aug-23-23 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
12:31PM	Health Care Roundup: Market Talk (The Wall Street Journal)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MURPHY ANDREW J	EVP Research	Dec 05	Sale	817.44	6,536	5,342,787	59,421	Dec 06 04:02 PM
MURPHY ANDREW J	EVP Research	Dec 04	Option Exercise	270.43	20,000	5,408,600	79,421	Dec 06 04:02 PM
RYAN ARTHUR F	Director	Dec 01	Sale	817.30	100	81,730	18,447	Dec 04 04:02 PM
MURPHY ANDREW J	EVP Research	Nov 14	Sale	799.17	6,492	5,188,213	59,421	Nov 15 04:02 PM
MURPHY ANDREW J	EVP Research	Nov 13	Option Exercise	270.43	20,000	5,408,600	79,421	Nov 15 04:02 PM
RYAN ARTHUR F	Director	Nov 07	Sale	827.90	100	82,790	18,547	Nov 08 04:07 PM
McCourt Marion	EVP Commercial	Nov 01	Option Exercise	381.40	1,000	381,400	20,803	Nov 02 04:03 PM
McCourt Marion	EVP Commercial	Nov 01	Sale	783.91	1,000	783,910	19,803	Nov 02 04:03 PM
Zoghbi Huda Y	Director	Oct 13	Option Exercise	391.92	1,000	391,920	2,247	Oct 17 04:06 PM
Zoghbi Huda Y	Director	Oct 13	Sale	850.00	1,000	850,000	1,247	Oct 17 04:06 PM
McCourt Marion	EVP Commercial	Oct 02	Option Exercise	372.46	1,038	386,613	20,841	Oct 03 04:04 PM
McCourt Marion	EVP Commercial	Oct 02	Sale	827.00	1,038	858,426	19,803	Oct 03 04:04 PM
McCourt Marion	EVP Commercial	Sep 01	Sale	834.55	250	208,638	19,803	Sep 06 04:03 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Aug 24	Sale	841.71	6,197	5,216,073	21,508	Aug 25 04:02 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Aug 23	Option Exercise	381.40	23,125	8,819,875	44,633	Aug 25 04:02 PM
POON CHRISTINE A	Director	Aug 23	Option Exercise	273.67	12,280	3,360,668	14,317	Aug 25 04:02 PM
Fenimore Christopher R.	SVP Controller	Aug 23	Option Exercise	399.66	7,000	2,797,620	26,140	Aug 25 04:03 PM
POON CHRISTINE A	Director	Aug 23	Sale	839.97	12,280	10,314,829	2,037	Aug 25 04:02 PM
Landry Robert E	EVP Finance CFO	Aug 23	Sale	844.00	223	188,212	31,699	Aug 25 04:02 PM
STAHL NEIL	EVP Research and Development	Aug 22	Sale	840.98	11,665	9,810,082	53,100	Aug 23 04:03 PM
STAHL NEIL	EVP Research and Development	Aug 21	Option Exercise	399.66	50,000	19,983,000	103,100	Aug 23 04:03 PM
Bassler Bonnie L	Director	Aug 21	Option Exercise	391.92	853	334,308	2,100	Aug 23 04:03 PM
Bassler Bonnie L	Director	Aug 21	Sale	829.00	853	707,137	1,247	Aug 23 04:03 PM
Bassler Bonnie L	Director	Aug 10	Option Exercise	391.92	853	334,308	2,100	Aug 11 04:13 PM
Bassler Bonnie L	Director	Aug 10	Sale	789.00	853	673,017	1,247	Aug 11 04:13 PM
McCourt Marion	EVP Commercial	Aug 01	Sale	744.66	250	186,165	20,053	Aug 03 04:02 PM
RYAN ARTHUR F	Director	Aug 01	Sale	736.59	100	73,659	18,647	Aug 03 04:25 PM
McCourt Marion	EVP Commercial	Jul 03	Sale	710.09	250	177,522	20,303	Jul 06 04:02 PM
RYAN ARTHUR F	Director	Jul 03	Sale	716.88	100	71,688	18,747	Jul 06 04:01 PM
McCourt Marion	EVP Commercial	Jun 01	Sale	736.00	250	184,000	20,553	Jun 02 04:12 PM
RYAN ARTHUR F	Director	Jun 01	Sale	735.42	100	73,542	18,847	Jun 02 04:14 PM
RYAN ARTHUR F	Director	May 01	Sale	805.33	100	80,533	18,947	May 03 04:01 PM
BROWN MICHAEL S	Director	Apr 21	Option Exercise	520.01	3,070	1,596,431	4,317	Apr 24 04:05 PM
BROWN MICHAEL S	Director	Apr 21	Sale	798.42	3,070	2,451,149	1,247	Apr 24 04:05 PM
McCourt Marion	EVP Commercial	Apr 03	Option Exercise	372.46	1,100	409,706	21,903	Apr 05 04:00 PM
McCourt Marion	EVP Commercial	Apr 03	Sale	818.80	1,100	900,680	20,803	Apr 05 04:00 PM
RYAN ARTHUR F	Director	Apr 03	Sale	819.31	100	81,931	19,047	Apr 05 04:01 PM
Landry Robert E	EVP Finance CFO	Mar 28	Sale	823.47	1,007	829,233	31,922	Mar 29 04:07 PM
Landry Robert E	EVP Finance CFO	Mar 27	Option Exercise	379.60	3,800	1,442,476	35,316	Mar 29 04:07 PM
Landry Robert E	EVP Finance CFO	Mar 27	Sale	821.70	183	150,372	32,929	Mar 29 04:07 PM
Bassler Bonnie L	Director	Mar 24	Option Exercise	380.95	1,240	472,378	2,487	Mar 27 04:43 PM
Bassler Bonnie L	Director	Mar 24	Sale	818.00	1,240	1,014,320	1,247	Mar 27 04:43 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Mar 23	Option Exercise	270.43	10,000	2,704,300	34,213	Mar 27 04:39 PM
YANCOPOULOS GEORGE	President and Chief Scientific	Mar 23	Sale	804.26	3,656	2,940,374	196,848	Mar 27 04:41 PM
Fenimore Christopher R.	SVP Controller	Mar 23	Sale	806.47	2,192	1,767,782	18,409	Mar 27 04:37 PM
McCourt Marion	EVP Commercial	Mar 01	Option Exercise	372.46	1,100	409,706	21,903	Mar 03 04:03 PM
McCourt Marion	EVP Commercial	Mar 01	Sale	759.89	1,100	835,879	20,803	Mar 03 04:03 PM
RYAN ARTHUR F	Director	Mar 01	Sale	762.50	100	76,250	19,147	Mar 03 04:03 PM
VAGELOS P ROY	Director	Feb 22	Option Exercise	270.43	42,500	11,493,275	366,583	Feb 24 04:07 PM
McCourt Marion	EVP Commercial	Feb 07	Option Exercise	372.46	1,000	372,460	23,079	Feb 08 04:14 PM
McCourt Marion	EVP Commercial	Feb 07	Sale	769.04	1,000	769,040	22,079	Feb 08 04:14 PM
GOLDSTEIN JOSEPH L	Director	Feb 06	Option Exercise	482.68	3,613	1,743,923	9,860	Feb 08 04:16 PM
BROWN MICHAEL S	Director	Feb 06	Option Exercise	520.01	3,071	1,596,951	4,318	Feb 08 04:15 PM
YANCOPOULOS GEORGE	President and Chief Scientific	Feb 06	Sale	800.08	13,189	10,552,255	200,504	Feb 08 04:15 PM
GOLDSTEIN JOSEPH L	Director	Feb 06	Sale	800.00	3,613	2,890,400	6,247	Feb 08 04:16 PM
BROWN MICHAEL S	Director	Feb 06	Sale	798.00	3,071	2,450,658	1,247	Feb 08 04:15 PM
Landry Robert E	EVP Finance CFO	Feb 06	Sale	788.88	752	593,238	32,105	Feb 07 04:09 PM
BROWN MICHAEL S	Director	Feb 06	Sale	797.00	500	398,500	6,162	Feb 08 04:15 PM
Fenimore Christopher R.	SVP Controller	Feb 03	Option Exercise	270.43	5,000	1,352,150	23,581	Feb 07 04:10 PM
Landry Robert E	EVP Finance CFO	Feb 03	Option Exercise	381.92	3,000	1,145,760	35,105	Feb 07 04:09 PM
Bassler Bonnie L	Director	Feb 03	Option Exercise	380.95	1,021	388,950	2,268	Feb 07 04:09 PM
Bassler Bonnie L	Director	Feb 03	Sale	779.00	1,021	795,359	1,247	Feb 07 04:09 PM
Landry Robert E	EVP Finance CFO	Feb 03	Sale	764.50	739	564,966	32,105	Feb 07 04:09 PM
McCourt Marion	EVP Commercial	Feb 01	Option Exercise	372.46	1,100	409,706	23,179	Feb 03 04:13 PM
McCourt Marion	EVP Commercial	Feb 01	Sale	752.19	1,100	827,409	22,079	Feb 03 04:13 PM
RYAN ARTHUR F	Director	Feb 01	Sale	756.13	100	75,613	19,247	Feb 03 04:15 PM
BROWN MICHAEL S	Director	Jan 27	Option Exercise	520.01	1	520	1,248	Jan 30 04:11 PM
BROWN MICHAEL S	Director	Jan 27	Sale	747.00	1	747	1,247	Jan 30 04:11 PM
BROWN MICHAEL S	Director	Jan 06	Option Exercise	520.01	3,070	1,596,431	4,317	Jan 10 04:03 PM
BROWN MICHAEL S	Director	Jan 06	Sale	747.14	3,070	2,293,720	1,247	Jan 10 04:03 PM
McCourt Marion	EVP Commercial	Jan 03	Option Exercise	372.46	1,100	409,706	23,179	Jan 05 04:22 PM
McCourt Marion	EVP Commercial	Jan 03	Sale	721.86	1,100	794,046	22,079	Jan 05 04:22 PM
RYAN ARTHUR F	Director	Jan 03	Sale	726.29	100	72,629	19,182	Jan 05 04:37 PM
COLES N ANTHONY	Director	Dec 28	Option Exercise	442.24	5,758	2,546,410	6,851	Dec 30 04:10 PM
COLES N ANTHONY	Director	Dec 28	Sale	714.11	5,758	4,111,822	1,093	Dec 30 04:10 PM
McCourt Marion	EVP Commercial	Dec 12	Sale	730.17	264	192,765	19,106	Dec 13 04:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc.

Upgrade your FINVIZ experience